An open-label, phase 2b, global multicenter cohort trial to access the Safety and Efficacy of Ziperlatinib in Patients with locally advanced or metastatic non-small-cell lung cancer with Exon 20 Insertion and uncommon/single or compound epidermal groth factor receptor mutations.
